{"id":"ciprofloxacin-0-3","safety":{"commonSideEffects":[{"rate":null,"effect":"Local irritation (burning, stinging)"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Photophobia"},{"rate":null,"effect":"Lid margin crusting"}]},"_chembl":{"chemblId":"CHEMBL8","moleculeType":"Small molecule","molecularWeight":"331.35"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ciprofloxacin works by binding to and inhibiting bacterial DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for DNA replication and transcription. This leads to rapid bactericidal activity against a broad spectrum of gram-negative and gram-positive bacteria. The 0.3% ophthalmic formulation is used topically on the eye to treat bacterial infections.","oneSentence":"Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:30:02.734Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial conjunctivitis"},{"name":"Corneal ulcers"},{"name":"Other bacterial eye infections"}]},"trialDetails":[{"nctId":"NCT06342830","phase":"PHASE2","title":"Comparing the Effect of Different Intracanal Dressing on Failed Root Canal Treated Cases on Periapical Healing","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2024-06-20","conditions":"Periapical Disease","enrollment":60},{"nctId":"NCT05804123","phase":"NA","title":"LiveSpo Navax® Supports the Treatment of Acute Rhinosinusitis and Otitis Media","status":"COMPLETED","sponsor":"Anabio R&D","startDate":"2021-10-28","conditions":"Upper Respiratory Tract Infections","enrollment":175},{"nctId":"NCT05133258","phase":"","title":"Antibiotic Concentration After Delivery to Middle Ear for Chronic Suppurative Otitis Media","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2022-07-05","conditions":"Chronic Suppurative Otitis Media","enrollment":3},{"nctId":"NCT00961675","phase":"PHASE3","title":"FST-201 in the Treatment of Acute Otitis Externa","status":"COMPLETED","sponsor":"Shire","startDate":"2009-08-31","conditions":"Acute Otitis Externa","enrollment":70},{"nctId":"NCT02216071","phase":"PHASE3","title":"Comparative Efficacy and Safety of Ciprofloxacin 0.3% and Dexamethasone 0.1% in Acute Otitis Externa","status":"COMPLETED","sponsor":"Exela Pharma Sciences, LLC.","startDate":"2014-07-20","conditions":"Acute Otitis Externa","enrollment":499},{"nctId":"NCT00945802","phase":"PHASE3","title":"FST-201 In The Treatment of Acute Otitis Externa","status":"TERMINATED","sponsor":"Shire","startDate":"2009-07-31","conditions":"Acute Otitis Externa","enrollment":5},{"nctId":"NCT04636957","phase":"PHASE3","title":"A Phase III Study of Ciprofloxacin Plus Fluocinolone in Acute Otitis Externa (AOE)","status":"UNKNOWN","sponsor":"Lee's Pharmaceutical Limited","startDate":"2020-11","conditions":"Acute Otitis Externa","enrollment":600},{"nctId":"NCT04204954","phase":"PHASE2, PHASE3","title":"Evaluation of Treatment Option for Demodicosis in Patients Undergoing Cataract Surgery","status":"COMPLETED","sponsor":"Hospital de La Luz","startDate":"2019-05-06","conditions":"Demodex Infestation, Demodicosis, Cataract","enrollment":160},{"nctId":"NCT00956748","phase":"PHASE4","title":"N-Acetylcysteine as an Adjunct for Refractory Chronic Suppurative Otitis Media","status":"WITHDRAWN","sponsor":"St. Paul's Hospital, Canada","startDate":"2019-11-29","conditions":"Otitis Media, Otorrhea","enrollment":""},{"nctId":"NCT03519516","phase":"PHASE1","title":"Safety and Tolerability of the PRO-174 Versus Sophixín Ofteno®, on the Ocular Surface of Healthy Subjects","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2018-01-25","conditions":"Conjunctivitis, Conjunctivitis, Bacterial","enrollment":30},{"nctId":"NCT01518842","phase":"NA","title":"Effect of Intravitreal Bone Marrow Stem Cells on Ischemic Retinopathy","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"2011-09","conditions":"Ischemia","enrollment":30},{"nctId":"NCT03347461","phase":"PHASE4","title":"Otiprio Versus Ciprodex Tympanostomy Tube Outcomes","status":"WITHDRAWN","sponsor":"Boston Medical Center","startDate":"2018-10","conditions":"Otorrhea, Otitis Media With Effusion in Children","enrollment":""},{"nctId":"NCT01908803","phase":"PHASE2","title":"Proof-of-Concept Study of a Single Application of an Investigational Otic Suspension in Treatment of Acute Otitis Media With Tympanostomy Tubes","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2013-12","conditions":"Acute Otitis Media","enrollment":84},{"nctId":"NCT02223338","phase":"NA","title":"Bacterial Resistance in Patients Receiving Post-Intravitreal Injection Antibiotics","status":"COMPLETED","sponsor":"Loma Linda University","startDate":"2014-10","conditions":"Bacterial Resistance","enrollment":120},{"nctId":"NCT01994642","phase":"PHASE3","title":"Bioequivalence of Two Ciprofloxacin 0.3%/Dexamethasone 0.1% Sterile Otic Suspensions in Otitis Media in Children With Tympanostomy Tubes","status":"TERMINATED","sponsor":"Par Pharmaceutical, Inc.","startDate":"2013-11","conditions":"Otitis Media in Patients With Tympanostomy Tubes","enrollment":203},{"nctId":"NCT01560715","phase":"PHASE2","title":"Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2011-06","conditions":"Retinitis Pigmentosa","enrollment":50},{"nctId":"NCT01910155","phase":"PHASE3","title":"A Bioequivalence Study of Two Ciprofloxacin/Dexamethasone Formulations in Patients With Otitis Externa","status":"TERMINATED","sponsor":"Par Pharmaceutical, Inc.","startDate":"2013-07","conditions":"Otitis Externa","enrollment":455},{"nctId":"NCT00392275","phase":"PHASE4","title":"Penetrance of Third Generation Fluoroquinolones in Eyes With Functioning Filtering Blebs","status":"COMPLETED","sponsor":"Indiana University School of Medicine","startDate":"2002-11","conditions":"Cataract","enrollment":48},{"nctId":"NCT01027494","phase":"","title":"Topical Treatment of Acute Otitis Media Through Tympanostomy Tubes (AOMT) and Its Effect on Microbial Flora","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2009-12","conditions":"Acute Otitis Media","enrollment":318},{"nctId":"NCT01359098","phase":"PHASE2","title":"Efficacy and Safety of Once-Daily Ciprodexa Otic Foam Compared to Twice-daily Ciprodex Ear Drops in Acute Otitis Externa","status":"COMPLETED","sponsor":"Otic Pharma","startDate":"2011-07","conditions":"Otitis Externa, Otorhinolaryngologic Diseases, Ear Diseases","enrollment":100},{"nctId":"NCT01068561","phase":"PHASE1","title":"Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2009-05","conditions":"Retinitis Pigmentosa","enrollment":5},{"nctId":"NCT01157819","phase":"PHASE2","title":"Safety and Efficacy of Once-Daily Dosing of FoamOtic Cipro Compared to Twice-Daily Dosing of Ciloxan Ear Drops in Patients With Acute External Otitis","status":"COMPLETED","sponsor":"Otic Pharma","startDate":"2010-07","conditions":"Otitis Externa, Otorhinolaryngologic Diseases, Ear Diseases","enrollment":70},{"nctId":"NCT00872209","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Foam Otic Cipro Compared to a Standard Solution ( Ciloxan - Alcon Labs ) to Treat Acute Otitis Externa","status":"COMPLETED","sponsor":"Otic Pharma","startDate":"2009-05","conditions":"Otitis Externa, Otorhinolaryngologic Diseases, Ear Diseases","enrollment":100},{"nctId":"NCT00651586","phase":"PHASE2","title":"Safety and Efficacy Study of Gatifloxacin Compared With Ciprofloxacin in Patients With Acute Bacterial Corneal Ulcers","status":"COMPLETED","sponsor":"Allergan","startDate":"2003-10","conditions":"Acute Bacterial Corneal Ulcers, Bacterial Keratitis","enrollment":129},{"nctId":"NCT00431028","phase":"PHASE1, PHASE2","title":"Sub-Tenon's Injection of Triamcinolone and Ciprofloxacin in a Controlled-Release System for Cataract Surgery","status":"TERMINATED","sponsor":"Federal University of São Paulo","startDate":"2005-09","conditions":"Inflammation, Bacterial Infections","enrollment":140}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":121,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CETRAXAL OTICO®"],"phase":"marketed","status":"active","brandName":"Ciprofloxacin 0.3%","genericName":"Ciprofloxacin 0.3%","companyName":"Indiana University School of Medicine","companyId":"indiana-university-school-of-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription. Used for Bacterial conjunctivitis, Corneal ulcers, Other bacterial eye infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}